Enliven Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on the stock and has a $39.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sam Slutsky has given his Buy rating due to a combination of factors that highlight Enliven Therapeutics’ promising future. The company’s lead asset, ELVN-001, is a BCR::ABL1 active site tyrosine kinase inhibitor in development for chronic myeloid leukemia (CML). Recent Phase 1 data showed a significant major molecular response rate in a heavily pretreated population, along with good tolerability, indicating strong potential for this treatment.
Furthermore, Enliven’s financial position is robust, with $477.6 million in cash and equivalents, providing a runway into the first half of 2029. This financial stability supports the company’s plans to initiate a pivotal study with ELVN-001 in 2026, targeting the 2L+ setting. The potential for ELVN-001 to become a key option in the CML treatment landscape, especially post-Scemblix, further strengthens the Buy recommendation.
According to TipRanks, Slutsky is a 5-star analyst with an average return of 27.4% and a 48.77% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Astria Therapeutics, and Celldex.
In another report released on November 3, Mizuho Securities also maintained a Buy rating on the stock with a $41.00 price target.